KEGG   DRUG: Rabeprazole, amoxicillin and clarithromycin
Entry
D10519            Mixture   Drug                                   

Name
Rabeprazole, amoxicillin and clarithromycin;
Rabecure (TN)
Component
(Sodium rabeprazole [DR:D00724] | Rabeprazole [DR:D08463]), (Amoxicillin hydrate [DR:D00229] | Amoxicillin [DR:D07452]), Clarithromycin [DR:D00276]
Remark
Therapeutic category: 6199
ATC code: A02BD12
Product: D10519<JP>
Efficacy
Antibacterial
Comment
Rabeprazole sodium is a substrate of CYP2C19 and CYP3A4.
Clarithromycin is an inhibitor and a substrate of CYP3A4, and it is an inhibitor of P-gp.
Metabolism
Enzyme: CYP2C19 [HSA:1557], CYP3A4 [HSA:1576]
Interaction
CYP inhibition: CYP3A4 [HSA:1576]
Transporter inhibition: ABCB1 [HSA:5243]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A02 DRUGS FOR ACID RELATED DISORDERS
   A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
    A02BD Combinations for eradication of Helicobacter pylori
     A02BD12 Rabeprazole, amoxicillin and clarithromycin
      D10519  Rabeprazole, amoxicillin and clarithromycin <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  61  Antibiotics
   619  Miscellaneous
    6199  Miscellaneous
     D10519  Rabeprazole, amoxicillin and clarithromycin
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10519
 Drug transporters
  D10519
Other DBs
PubChem: 254741481
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system